At Alnylam Pharma we have been working in partnership with the UK Biobank to assess genetic and phenotypic data, biomarker data, MRI scans and medical imaging to understand which genes to go after for a particular disease. We have specific use cases and lessons learned and this fireside chat will discuss:

• Repurposing technology to train neural network models
• How to ascertain which genes to go after when scanning data?
• How can we link this to genetic data?